Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SLI 381

Drug Profile

SLI 381

Alternative Names: Adderall XR; Amfetamine salts (mixed, extended release) - Takeda; Amphetamine salts (mixed, extended release) - Takeda; d,l-Amphetamine and d-amphetamine salts (extended release) - Takeda; d,l-Amphetamine and dextroamphetamine salts (extended release) - Takeda; d-Amphetamine and d,l-amphetamine salts (extended release) - Takeda; Dexamfetamine and d,l-amfetamine salts (extended release) - Takeda; Dextroamphetamine and d,l-amphetamine salts (extended release) - Takeda

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Class Amphetamines; Behavioural disorder therapies
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 23 Mar 2018 US District Court of Massachusetts issues a ruling against Abhai's marketing of a generic version of Shire's SLI 381
  • 20 Feb 2018 Shire has patent protection for SLI 381 in USA
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top